Clinical trial
Exacerbation Risk in Asthma
NCT05501639 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Exacerbation Risk in Asthma
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 14, 2021
- Completion date
- November 2, 2021
- Enrollment
- 1,899 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.